COMPANY NEWS
1 min read
REPLAY | FebriDx US Launch Update
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales
Read article
Products
Point-of-care technologies supported by global distribution channels.
Learn more
Services
Custom development, manufacturing and support for diagnostic products.
Learn more
Team
Our expert team develops, manufactures and commercializes point-of-care technologies.
Learn more
Invest
Lumos is an ASX-listed company (ASX:LDX). A compelling investment opportunity.
Learn moreWelcome to Lumos
World-class point-of-care products
Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately assess, diagnose and manage medical conditions.
FebriDx®
Rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial infection and non-bacterial etiology.
Lumos Development & Contract Manufacturing Services
Lumos specializes in rapid, cost-effective and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. We offer customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.
How Lumos can help your business
Strategic Innovation
Initial evaluation of a point-of-care diagnostic test product concept and the development of new diagnostic test assay.
Development and Manufacturing Transfer
Development of new point-of-care diagnostic test products, including use of Lumos technology platform and the customization and integration of Lumos digital reader technology when requested by Lumos clients.
Validation and Commercial Manufacturing
Clinical and product validation and commercial-scale manufacture of test strips and readers.
Medical, Quality and Regulatory Affairs
In house, qualified team to support all stages of product development and commercialization.
FebriDx featured on Channel 9 News, Australia
Learn more about the Australian roll-out of FebriDx
This device is now available via qualified clinicians to help patients more accurately navigate the need for antibiotics.
Lumos News
View all news
COMPANY NEWS
COMPANY NEWS
2 min read
100+ Locations and Growing: A Milestone for FebriDx® Adoption
FebriDx® has surpassed 100 healthcare locations across 18 states in the United States
Read article
COMPANY NEWS
1 min read
Lumos Achieves 250 Patient Milestone in FebriDx® Paediatric Study
Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment...
Read articleSubscribe for Lumos news and investor updates
By entering your email address you are agreeing to our Privacy Policy.